Comparison (t-test) between 23vPPV and PCV7 for OPA in GMT (titre⁻¹).

a

Ratio of PCV7 to 23vPPV.

b

The number of samples tested for each stereotype varied depending on volume of available sera and ranged from 59–103.

c

The number of samples tested for each stereotype varied depending on volume of available sera and ranged from 57–99.

d

The number of samples tested for each stereotype varied depending on volume of available sera and ranged from 57–96.

e

The number of samples tested for each stereotype varied depending on volume of available sera and ranged from 60–103.

f

The number of samples tested for each stereotype varied depending on volume of available sera and ranged from 76–116.

g

The number of samples tested for each stereotype varied depending on volume of available sera and ranged from 84–127.

Sig difference identified by ELISA for 9V also identified by OPA and persisted to 12 months. Also, sig higher OPA for 23F in PCV7 group at 6 months which persisted at 12 months. Significantly higher OPA at 6 months for 23vPPV group for 19A and 19F – more marked for 19A - which was abolished at 12 months' time point (6 months post 23vPPV booster).